Canada Archives - Page 2 of 4 - 2021 CMSC Annual Meeting

October 25, 2021

Influence of Imaging Parameters on MRI Contrast Using Qualitymetrix

Background: Acquiring brain magnetic resonance images (MRI) with sufficient tissue contrast is important for supporting diagnosis and...

Read More →

Poster-Epidemiology and Genetics

October 25, 2021

Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)

Background: NARCRMS is a longitudinal registry studying the course of MS in the disease-modifying era. Objectives: To examine motor...

Read More →

Poster-Family and Caregivers

October 25, 2021

Profiles of Resilience Among MS Care Partners

Background: Psychological resilience may play an important role in protecting multiple sclerosis (MS) care-partners from the negative...

Read More →

Poster-Imaging

October 25, 2021

Compliance of a Real-World Dataset with the CMSC 2018 Guidelines

Background: Acquiring brain magnetic resonance images (MRI) in a standardized way, following CMSC guidelines, increases image consistency...

Read More →

Poster-Imaging

October 25, 2021

First Steps Towards Implementation of a Standardized MRI Protocol to Improve Care for People with MS in British Columbia

Background: Magnetic resonance imaging (MRI) is important in the diagnosis and monitoring of people with multiple sclerosis (MS). Using a...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefitrisk profile in patients with relapsing-remitting...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Post-Approval Safety of Subcutaneous Interferon ?-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

Background: Subcutaneous interferon ?-1a (sc IFN ?-1a) is a well-established disease-modifying therapy for relapsing multiple sclerosis...

Read More →

2021 CMSC Annual Meeting

Tag: Canada

Influence of Imaging Parameters on MRI Contrast Using Qualitymetrix

Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)

Profiles of Resilience Among MS Care Partners

Compliance of a Real-World Dataset with the CMSC 2018 Guidelines

First Steps Towards Implementation of a Standardized MRI Protocol to Improve Care for People with MS in British Columbia

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Post-Approval Safety of Subcutaneous Interferon ?-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

MAILING ADDRESS

CONTACT US

FOLLOW US